Cargando…

Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer

Detalles Bibliográficos
Autores principales:	Bendell, Johanna C., Rosen, Lee S., Mayer, Robert J., Goldman, Jonathan W., Infante, Jeffrey R., Benedetti, Fabio, Lin, Donghu, Mizuguchi, Hirokazu, Zergebel, Christopher, Patel, Manish R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2015
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969883/ https://www.ncbi.nlm.nih.gov/pubmed/26589791 http://dx.doi.org/10.1007/s00280-015-2890-9

Ejemplares similares

Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
por: Bendell, Johanna C., et al.
Publicado: (2015)

Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors
por: Bendell, Johanna C., et al.
Publicado: (2016)

Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
por: Sugiura, Kiyoaki, et al.
Publicado: (2021)

Efficacy and safety of TAS-102 in refractory metastatic colorectal cancer: a meta-analysis
por: Chen, Duke, et al.
Publicado: (2018)

Tas-102 for Refractory Metastatic Colorectal Cancer: A Multicenter Retrospective Cohort Study
por: Conti, Matteo, et al.
Publicado: (2023)

A meta-analysis comparing regorafenib with TAS-102 for treating refractory metastatic colorectal cancer
por: Su, Guan-Li, et al.
Publicado: (2020)

A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Chen, Xiaochen, et al.
Publicado: (2021)

TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
por: Liu, Cheng-Jiang, et al.
Publicado: (2021)

TAS-102 and the quest for predictive biomarkers
por: van der Velden, Daphne L, et al.
Publicado: (2017)

Bevacizumab in Combination with TAS‐102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study
por: Fujii, Hironori, et al.
Publicado: (2019)

Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy
por: Huemer, Florian, et al.
Publicado: (2020)

Drug-induced Pneumonitis Following the Administration of TAS-102
por: Hasegawa, Yoshikazu, et al.
Publicado: (2016)

Difference in Neutropenia due to Administration Schedule of TAS-102
por: Yoshida, Yoichiro, et al.
Publicado: (2017)

Erratum to long-term chest CT follow-up in COVID-19 Survivors: 102–361 days after onset
Publicado: (2022)

Interstitial pneumonia in a patient treated with TAS-102 for metastatic colorectal cancer: a case report
por: Kamei, Hideki, et al.
Publicado: (2016)

Phase Ib/II Study of Biweekly TAS‐102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)
por: Satake, Hironaga, et al.
Publicado: (2020)

Erratum to comprehensive bioinformatics analysis of the TP53 signaling pathway in Wilms’ tumor
por: He, Changjing, et al.
Publicado: (2021)

TAS-102, the first “cardio-gentle” fluoropyrimidine in the colorectal cancer landscape?
por: Petrelli, Fausto, et al.
Publicado: (2016)

Erratum to: Pseudo-cardiac tamponade owing to a large hiatal hernia
por: Tsuchida, Takumi, et al.
Publicado: (2021)

Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study
por: Kasi, Pashtoon M., et al.
Publicado: (2016)

Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report
por: Li, Qizheng, et al.
Publicado: (2022)

The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer
por: Van Cutsem, Eric, et al.
Publicado: (2017)

Erratum to “Hand Surgery Patient Perspectives on Medical Cannabis: A Survey of Over 600 Patients” [Journal of Hand Surgery Global Online 5 (2023) 102-107]
por: Fones, Lilah, et al.
Publicado: (2023)

June 2014 Issue, vol.102 (6), pages 611-612
Publicado: (2014)

Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
por: Kotani, Daisuke, et al.
Publicado: (2019)

Erratum to: Metastatic Merkel cell carcinoma response to nivolumab
por: Walocko, Frances M., et al.
Publicado: (2017)

Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours
por: Doi, T, et al.
Publicado: (2012)

Apatinib in refractory radiation-induced brain Edema: A case report: Erratum
Publicado: (2017)

Apatinib in refractory radiation-induced brain Edema: A case report: Erratum
Publicado: (2018)

Refractoriness of aggressive behaviour to pharmacological treatment: cortical thickness analysis in autism spectrum disorder – ERRATUM
por: Gouveia, Flavia Venetucci, et al.
Publicado: (2020)

Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with (90)Y resin microspheres for chemo-refractory colorectal liver metastases
por: Fidelman, Nicholas, et al.
Publicado: (2022)

Erratum to: Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma
por: Okuma, Yusuke, et al.
Publicado: (2016)

Erratum for Concurrent use of rabacfosadine and L‐asparaginase for relapsed or refractory multicentric lymphoma in dogs
Publicado: (2020)

Edition of March 2014, vol. 102 (3), Supl. 1, pg. 1-61
Publicado: (2014)

Effect of food on the pharmacokinetics of TAS‐102 and its efficacy and safety in patients with advanced solid tumors
por: Yoshino, Takayuki, et al.
Publicado: (2016)

Erratum to: The use of simultaneous stereo-electroencephalography and magnetoencephalography in localizing the epileptogenic focus in refractory focal epilepsy
Publicado: (2021)

Erratum for “Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide”
por: El-Amm, Joelle, et al.
Publicado: (2013)

Erratum
por: Wincent, Josephine, et al.
Publicado: (2016)

Erratum to: Outcome of maintenance systemic chemotherapy with drug-free interval for metastatic urothelial carcinoma
por: Abe, T, et al.
Publicado: (2020)

Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial
por: Longo-Muñoz, F., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ab647p21lba31fv9ees7prljha